The Effects of the Thoracoabdominal Aortic Metabolism on the Endovascular Procedures Outcomes
International Journal of Cardiovascular and Thoracic Surgery
Volume 4, Issue 4, July 2018, Pages: 30-33
Received: Jul. 30, 2018; Accepted: Aug. 15, 2018; Published: Sep. 17, 2018
Views 451      Downloads 53
Authors
Novotny Robert, Institute for Clinical and Experimental Medicine, Transplant Surgery Department, Prague, Czech Republic
Jaroslav Chlupac, Institute for Clinical and Experimental Medicine, Transplant Surgery Department, Prague, Czech Republic
Libor Janousek, Institute for Clinical and Experimental Medicine, Transplant Surgery Department, Prague, Czech Republic; Second Faculty of Medicine, Charles University, Prague, Czech Republic
Jiri Fronek, Institute for Clinical and Experimental Medicine, Transplant Surgery Department, Prague, Czech Republic; First Faculty of Medicine, Charles University, Prague, Czech Republic
Article Tools
Follow on us
Abstract
Aortic metabolism is a merge of complex processes. Atherosclerotic infiltration of the aortic wall is a crucial factor when choosing an appropriate endovascular treatment modality for anatomically suitable patients. Due to the rise of endovascular treatments and placement of endovascular devices in younger patients, many physicians are starting to take a more considerable interest in this complex process. Many experimental animal models are used for elucidation of individual aspects in this area. This led to an in-depth explanation of many metabolic processes of the aortic wall. However, only a few papers are reporting on the assessment of these pathological processes in human tissues. This paper outlines some of the crucial aspects of the thoracoabdominal aortic metabolism. Final results of endovascular treatments are believed to be significantly affected by the quality of the aortic wall and the ability to predict its further changes. This includes the pathological changes and their effects on the symbiotic metabolic changes. “Patient-tailored” endovascular aortic treatments based on the aortic metabolic assessment may be able to optimise the cases outcomes. Due to the rise of endovascular treatments and placement of endovascular devices in younger patients, further research is needed to understand better aortic metabolic processes in various patient groups, including groups of patients suffering from chronic metabolic diseases. Aortic wall metabolism should be assessed with the aim to optimise the endovascular treatment outcomes.
Keywords
Abdominal Aorta, Thoracic Aorta, Metabolism, Oxygen Consumption, Differences
To cite this article
Novotny Robert, Jaroslav Chlupac, Libor Janousek, Jiri Fronek, The Effects of the Thoracoabdominal Aortic Metabolism on the Endovascular Procedures Outcomes, International Journal of Cardiovascular and Thoracic Surgery. Vol. 4, No. 4, 2018, pp. 30-33. doi: 10.11648/j.ijcts.20180404.11
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Landry G, Lau I, Liem T, Mitchell E, Moneta G. Open abdominal aortic aneurysm repair in the endovascular era: effect of clamp site on outcomes. Arch Surg. 2009 Sep; 144 (9):811-6. doi: 10.1001/archsurg.2009.157.
[2]
Sigman MM, Palmer OP, Ham SW, Cunningham M, Weaver FA. Aortic morphologic findings after thoracic endovascular aortic repair for type B aortic dissection. JAMA Surg. 2014 Sep; 149 (9):977-83. doi: 10.1001/jamasurg.2014.1327.
[3]
Boyed W., A Text-Book of Pathology, Philadelphia, Lea& Febinger, 5th edition, 1947, 402.
[4]
Lazarovskaya L. N, Change in respiration of blood vessels with age, Biokhimiya, 1943, 8, 171.
[5]
Briggs F. N., Chermick S., Chaickoff I. L., The metabolism of arterial tissue. I. Respiration of rat thoracic aorta, J. Biol. Chem., 1949, 179, 103.
[6]
Henderson A. E., MacDougall J. D. B., The respiration of arterial tissue, Biochem. J., 1956, 62, 517.
[7]
Asakura T, Karino T. Flow patterns and spatial distribution of atherosclerotic lesions in human coronary arteries. Circ. Res., 1990, 66:1045–1066.
[8]
Velican C., Velican D. Differences in the pattern of atherosclerotic involvement between non-branched regions and adjacent branching points of human coronary arteries. Atherosclerosis. 1985 Mar; 54 (3):333-42.
[9]
Sakata N, Takebayashi S. Localization of atherosclerotic lesions in the curving sites of human internal carotid arteries. Biorheology. 1988; 25 (3):567-78.
[10]
Dayton S, Hashimoto S. Recent advances in molecular pathology: a review. Cholesterol flux and metabolism in arterial tissue and in atheromata. Exp Mol Pathol., 1970 Oct; 13 (2):253-68.
[11]
Schwenke DC, Carew TE. Determination of LDL degradation rate, content, and residence time in lesioned and nonlesioned aorta. Circulation, 1987, 76: IV-313.
[12]
Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis, 1989, 9:908–918.
[13]
Tozer EC, Carew TE. The residence time of low-density lipoprotein in the normal and atherosclerotic rabbit aorta. Circ Res, 1997, 80:208–218.
[14]
Schwenke DC. Metabolic evidence for sequestration of low-density lipoprotein in the abdominal aorta of normal-rabbits. Am J Physiol Heart Circ Physiol. 2000 Sep; 279 (3): H1128-40.
[15]
Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, Camejo G. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol, 1997 17:1011–1017.
[16]
Almuhaideb A, Papathanasiou N, Bomanji J. 18F-FDG PET/CT Imaging In Oncology. Annals of Saudi Medicine. 2011; 31 (1):3-13. doi:10.4103/0256-4947.75771.
[17]
Kotze CW, Groves AM, Menezes LJ, Harvey R, Endozo R, Kayani IA, et al. What is the relationship between 18F-FDG aortic aneurysm uptake on PET/CT and future growth rate? Eur J Nucl Med Mol Imaging. 2011 Aug; 38 (8):1493-9. doi: 10.1007/s00259-011-1799-8. Epub 2011 Apr 6.
[18]
Kotze CW, Menezes LJ, Endozo R, Groves AM, Ell PJ, Yusuf SW. Increased metabolic activity in abdominal aortic aneurysm detected by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT). Eur J Vasc Endovasc Surg. 2009 Jul; 38 (1):93-9. doi: 10.1016/j.ejvs.2008.12.016. Epub 2009 Feb 12.
[19]
Morel O, Mandry D, Micard E, Kauffmann C, Lamiral Z, Verger A. Evidence of Cyclic Changes in the Metabolism of Abdominal Aortic Aneurysms During Growth Phases: 18F -FDG PET Sequential Observational Study. J Nucl Med. 2015 Jul; 56 (7):1030-5. doi: 10.2967/jnumed.114.146415. Epub 2015 Mar 19.
[20]
Courtois A, Nusgens BV, Hustinx R, Namur G, Gomez P, Somja J, et al. 18F-FDG uptake assessed by PET/CT in abdominal aortic aneurysms is associated with cellular and molecular alterations prefacing wall deterioration and rupture. J Nucl Med. 2013 Oct; 54 (10):1740-7. doi: 10.2967/jnumed.112.115873. Epub 2013 Sep 5.
[21]
Michel JB, Martin-Ventura JL, Egido J, Sakalihasan N, Treska V, Lindholt J. Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc Res. 2011 Apr 1; 90 (1):18-27. doi: 10.1093/cvr/cvq337. Epub 2010 Oct 30.
[22]
Ben-Haim S, Kupzov E, Tamir A, Frenkel A, Israel O. Changing patterns of abnormal vascular wall F-18 fluorodeoxyglucose uptake on follow-up PET/CT studies. J Nucl Cardiol. 2006 Nov; 13 (6):791-800.
[23]
Menezes LJ, Kayani I, Ben-Haim S, Hutton B, Ell PJ, Groves AM. What is the natural history of 18F-FDG uptake in arterial atheroma on PET/CT? Implications for imaging the vulnerable plaque. Atherosclerosis. 2010 Jul; 211 (1):136-40. doi: 0.1016/j.atherosclerosis.2010.01.012.
[24]
Tatsumi M, Cohade C, Nakamoto Y, Wahl RL. Fluorodeox- glucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology 2003; 229:831e7.
[25]
Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical Renin-Angiotensin System in Kidney Physiology. Comprehensive Physiology. 2014; 4 (3):1201-1228. doi:10.1002/cphy.c130040.
[26]
Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical Renin-Angiotensin system in kidney physiology. Compr Physiol. 2014 Jul; 4 (3):1201-28. doi: 10.1002/cphy.c130040.
[27]
Cohn JN, Role of the renin-angiotensin system in cardiovascular disease. Cardiovasc Drugs Ther. 2010 Aug; 24 (4):341-4. doi: 10.1007/s10557-010-6230-3.
[28]
Koba S, Angiotensin II, Oxidative Stress, and Sympathetic Nervous System Hyperactivity in Heart Failure. Yonago Acta Med. 2018 Jun 18; 61 (2):103-109. eCollection 2018 Jun.
[29]
Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit. 2005 Jun; 11 (6): RA194-205. Epub 2005 May 25.
[30]
Sata M, Fukuda D. Crucial role of the renin-angiotensin system in the pathogenesis of atherosclerosis. J Med Invest. 2010 Feb; 57 (1-2):12-25.
[31]
Campbell DJ, Habener JF. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest. 1986 Jul; 78 (1):31-9.
[32]
Ijaz T, Sun H, Pinchuk IV, Milewicz DM, Tilton RG, Brasier AR. Deletion of NF-κB/RelA in Angiotensin II-Sensitive Mesenchymal Cells Blocks Aortic Vascular Inflammation and Abdominal Aortic Aneurysm Formation. Arterioscler Thromb Vasc Biol. 2017 Aug 17. pii: ATVBAHA.117.309863. doi: 10.1161/ATVBAHA.117.309863.
[33]
Bujak-Gizycka B, Olszanecki R, Suski M, Madek J, Stachowicz A, Korbut R. Angiotensinogen metabolism in rat aorta: robust formation of pro-angiotensin-12. J Physiol Pharmacol. 2010 Dec; 61 (6):679-82.
[34]
Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K. Isolation and identification of pro-angiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun. 2006 Dec 1; 350 (4):1026-31. Epub 2006 Oct 5.
[35]
Trask AJ, Jessup JA, Chappell MC, Ferrario CM. Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol Heart Circ Physiol. 2008 May; 294 (5): H2242-7. doi: 10.1152/ajpheart.00175.2008. Epub 2008 Mar 21.
[36]
Wołkow PP, Bujak-Giżycka B, Jawień J, Olszanecki R, Madej J, Rutowski J, et al. Exogenous Angiotensin I Metabolism in Aorta Isolated from Streptozotocin-Treated Diabetic Rats. J Diabetes Res. 2016; 2016:4846819. Epub 2016 Oct 10.
[37]
R. J. Head, P. A. Longhurst, R. L. Panek, R. E. Stitzel. A contrasting effect of the diabetic state upon the contractile responses of aortic preparations from the rat and rabbit. Br J Pharmacol. 1987 Jun; 91 (2): 275–286.
[38]
Czerny M, Grimm M, Zimpfer D, Rodler S, Gottardi R, Hutschala D, et al. Results after endovascular stent graft placement in atherosclerotic aneurysms involving the descending aorta. Ann Thorac Surg. 2007 Feb; 83 (2):450-5.
[39]
Hongku K, Sonesson B, Björses K, Holst J, Resch T, Dias NV. Mid-term Outcomes of Endovascular Repair of Ruptured Thoraco-abdominal Aortic Aneurysms with Off the Shelf Branched Stent Grafts. Eur J Vasc Endovasc Surg. 2018 Mar; 55 (3):377-384. doi: 10.1016/j.ejvs.2017.11.021. Epub 2018 Jan 4.
[40]
[40v Katzen B T. ENOVUS stent-graft: early clinical experience. J Endovasc Ther. 2004; 11: I22–I23.
[41]
Carpenter JP, Anderson W N, Brewster DC, et al. Multicenter pivotal trial results of the Lifepath System for endovascular aortic aneurysm repair. J Vasc Surg. 2004; 39:34–43.
ADDRESS
Science Publishing Group
548 FASHION AVENUE
NEW YORK, NY 10018
U.S.A.
Tel: (001)347-983-5186